Oct 26 (Reuters) - Biomarin Pharmaceutical Inc :Biomarin announces third quarter 2017 financial results.Q3 GAAP loss per share $0.07.Q3 earnings per share view $-0.14 -- Thomson Reuters I/B/E/S.Sees FY 2017 revenue $1.29 billion to …
* Biomarin Pharmaceuticals says expects to begin shipping just approved Brineura within 6 weeks * Biomarin says expected annual cost for Brineura to be $486,000 for ultra-rare pediatric brain disease * Biomarin says will have co-pay …
When major investors release their 13F filings each quarter, analysts scramble to make sense of the changes that those leaders have made to their investment portfolios over the past three months. This batch of 13F reports, detailing investor …
There is no committee data available. *Data is at least as current as the most recent Definitive Proxy. Request Profile Update The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, …
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $93.96 to a high of $95.89. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $94.94 on volume of …
Spark's positive vote by an FDA committee could be a boon for other drugmakers working on gene therapies including Audentes, BioMarin and Ultragenyx.